Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new drug combination is showing promise for lung cancer patients who've stopped responding to immunotherapy. In a randomized phase 1b trial, IBI363 plus bevacizumab cut the risk of disease progression or death by 60% compared to standard chemotherapy (docetaxel). The combo also nearly tripled the response rate, offering a potential new option for a patient population with very limited choices.
For patients with advanced lung adenocarcinoma whose cancer has become resistant to immunotherapy, treatment options are slim — and outcomes are often poor. A new phase 1b trial presented at the 2026 ESMO Congress is offering a glimmer of hope, showing that the investigational bispecific fusion protein IBI363 (TAK-928) combined with bevacizumab significantly outperformed standard docetaxel chemotherapy.
IBI363 works by simultaneously blocking PD-1 (a key immune checkpoint) and boosting IL-2 signaling to reactivate tumor-fighting T cells, while bevacizumab cuts off the tumor's blood supply via VEGF inhibition. Together, they appear to re-engage the immune system in patients where it had previously failed.
By the Numbers:
Why it matters: Immunotherapy resistance is a growing clinical challenge with no well-established standard of care. This trial suggests IBI363 plus bevacizumab could become a viable second-line option, especially for PD-L1–positive patients — and a phase 3 trial (MarsLight-11) is already underway to confirm these findings.
